GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
GRAIL, Inc. (GRAL)
Company Research
Source: GlobeNewswire
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. (NASDAQ: GRAL). If you have information that could assist in the GRAIL investigation or if you are a GRAIL investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-grail-inc-investigation-gral.html You can also contact attorney J.C. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. THE COMPANY: GRAIL is a commercial-stage healthcare company, providing multi-cancer early detection testing and services. THE REVELATION: On February 19, 2026, GRAIL announced results for its NHS-Galleri trial, which evaluated annual multi-cancer screening with GRAIL’s Galleri test, revealing that “[t]he primary endpoint of statistically significant Stage III-IV reduction was not observed.” On this news, the price of GRAIL stock
Show less
Read more
Impact Snapshot
Event Time:
GRAL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRAL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRAL alerts
High impacting GRAIL, Inc. news events
Weekly update
A roundup of the hottest topics
GRAL
News
- GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATESPR Newswire
- GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- BeOne Medicines (ONC) Reports $1.5B Revenue for Q4, $1.1B from Lymphoma Treatment [Yahoo! Finance]Yahoo! Finance
- GRAIL to Present at the TD Cowen 46th Annual Health Care ConferencePR Newswire
- GRAIL (NASDAQ:GRAL) was given a new $60.00 price target on by analysts at Morgan Stanley.MarketBeat